Delivery of Nucleic Acids and Nanomaterials by Cell-Penetrating Peptides: Opportunities and Challenges

Table 4

HA2 analogues and other sequence variations in CPPs to overcome lysosomal entrapment.

Name	Amino acid sequence	a.a. #	Structural order	Cargo	Purity	Efficiency	Ref.
HA2 analogues
	GLFEAIEGFIENGWEGMIDGWYG	23	pHA2-p53-R9	p53	N.A.	5x	[70]
	GDIMGEWGNEIFGAIAGFLG	20	pTat-Cre, pTat-HA2	No cargo	N.A.	2–6x	[71]
	GLFEAIEGFIENGWEGMIDGWYG	23	HA2-Tat	PM10	N.A.	0.5–1x	[72]
	pTat-HA-hARC or pTat-HA--gal		pTat-HA-hARC or pTat-HA--gal	-gal, ARC	N.A.	N.A.	[73]
	GLFEAIAEFIEGGWEGLIEGCAKKK	25	HA2-NT; (NT = neurotensin)	NT	>90%	22%	[74]
	GLFGAIAGFIENGQWGMIDG	20	HA2-Tat	FP	N.A.	N.A.	[75]
	GLFEAIEGFIENGWEGMIDGWYG	23	HA2-Tat	Shepherdin	>90%	3x	[76]
	GLFEAIEGFIENGWEGMIDGWYGC; GLFEAIEGFIENGWEGMIDGWYGC; (dimeric)	48	EGFR; siRNA/LF/diNF-7	EGFR; siRNA	N.A.	>2x	[77]
	GLFEAIEGFIENGWEGMIDGWYG	23	CPP-HA2	mCherry	N.A.	80–90x	[78]
	GLFEAIEGFIENGWEGMIDGWYG	23	GALA-INF	Luciferase	N.A.	>1000x	[79]
	GLLEALAELLE	11	HA2-CPP	FP	>95%	2x	[80]
Sequence variations in CPPs
10H	CHHHHHRKKRRQRRRRHHHHHC	22	C-5H-Tat-5H-C	Luciferase	>98%	>7000x	[81]
HR9	CHHHHHRRRRRRRRRHHHHHC	21	C-5H-R9-5H-C	DNAs, FPs, QDs	87%	20x	[43]
PasR8	FFLIPKGRRRRRRRRGC	17	Pas-CPP	Alexa 488	N.A.	18x	[82]
PR9	FFLIPKGRRRRRRRRR	16	Pas-CPP	DNAs, FPs, QDs	99%	47.5x	[44]
GALA	WEAALAEALAEALAEHLAEALAEALEALAA	30	GALA-EGFP	FITC	N.A.	68x	[83]

N.A. = not available.